| Orexigen: FDA Brings Good News for Obesity Drug Zacks.com submits: Recently Orexigen Therapeutics, Inc. (OREX) received a boost when the US Food and Drug Administration (FDA) accepted the New Drug Application for its candidate Contrave (naltrexone SR/bupropion SR). The candidate, a combination therapy, aims to address physiological and behavioral causes of obesity.The substantial amount of evidence gathered through the Contrave Obesity Research (COR) clinical program formed the basis of the application filed by the company in March 2010. The COR program studied more than 4,500 patients.Complete Story » seekingalpha.com |
Amgen Q2 2010 Earnings Call Transcript Amgen (AMGN)Q2 2010 Earnings CallJuly 29, 2010 5:00 pm ETComplete Story » seekingalpha.com |
FDA Rejects Jazz Drug as Treatment An FDA panel rejected a proposed Jazz Pharmaceuticals drug to treat the pain disorder fibromyalgia partly on concerns that the drug could be misused and abused. online.wsj.com |
Geron: Buyer Beware In recent days, shares of biopharma company Geron (GERN) have gone viral, up over 20% in a week. News of a clinical trial for an embryonic stem cell therapy aimed at spinal cord injuries has captured the imagination of investors. History should give them pause. I've followed Geron off and on since the company went public. Hoover's reports that the IPO took place on July 31, 1996 at a price of $8 a share. 2 million shares were offered, with a total of 9.7 million shares outstanding after the IPO was completed. The result: a company with an $80 million market value and a pocket full of cash.Complete Story » seekingalpha.com |
Insight Imaging Completes Sale of Seven Imaging Centers [Business Wire] - InSight Health Services Holdings Corp. today announced that it has completed the previously announced sale of seven imaging centers. Six centers were located in El Paso, Texas and Las Cruces, New Mexico and one imaging center in California. us.rd.yahoo.com |